Handheld ultrasound developer Signostics has announced a private investment of $35 million from KKR, a global investment firm.
The new funding from KKR will allow Signostics to pursue medical innovations and to expand and accelerate global marketing and distribution for new products. Prior to this transaction, Signostics changed the location of its corporate domicile from Australia to become a Delaware-based corporation with newly established headquarters in Kirkland, WA.
With the backing of this new investment, Signostics intends to deliver a growing suite of new devices designed to become a key element in the clinical professional's toolkit. The company said it will release a new product in 2016 and is beginning work on a series of advancements in ultrasound technology.
For KKR, the investment is part of the firm's healthcare growth equity strategy, which is focused on high-growth companies for which KKR can be a unique partner in helping reach scale.
